The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Andrea Demakas

Recent Posts

Using FAERS Data and Clinical Evidence to Compare HER2+ Antagonists

Posted by Andrea Demakas on Feb 9, 2017 7:30:00 AM

Recently, Advera Health released a comparative safety report of the HER2+ Antagonists. In this drug review, we analyzed FDA Adverse Event Reporting System (FAERS) and clinical trial data to better understand how the drugs in this class stacked up.

Read More

Topics: FAERS, Clinical Trials, Clinical Evidence, Breast Cancer

Safety Score & Cost Burden Analysis Update – Which Drugs have Riskiest Profiles?

Posted by Andrea Demakas on Jul 21, 2016 10:30:00 AM

In June, the Advera analyst team combed through prescription and patient population data supplied by our partners at Evaluate Pharma to update our RxScore and RxCost analytics site-wide. The end result yielded 53 drugs with first-time RxScores and 69 drugs with first-time RxCosts.

Read More

Topics: RxScore, P&T, RxCost

Honest Salespeople Aren’t Dead

Posted by Andrea Demakas on Jun 24, 2016 10:30:00 AM

I’m writing this in the lobby of a car dealership, waiting for my vehicle to get serviced. I brought a couple of sales books with me so I could utilize the 2 hour wait. I recently took on the added role of part-time sales rep within Advera Health as I have experienced successful case studies first-hand through being our client-facing Product Specialist over the past two years: I’ve built relationships with our existing clients, received their feedback on our data tools & analytics to see how they’ve implemented the information, and witnessed how our Evidex platform has become an integral part of their workflow.

Read More

Topics: FAERS, Payers, Formulary, Providers, Evidex

The Comparative Safety of Multiple Sclerosis Medications – A 2016 Update

Posted by Andrea Demakas on May 6, 2016 10:30:00 AM

If you subscribe to our monthly RxView Newsletter, then you probably saw the announcement that later in May, annotated data from curated clinical trial results for Multiple Sclerosis (MS) medications will be available in Evidex. Our coverage will include all approved drugs, as well as those in phase II development and above.

Read More

Topics: Multiple Sclerosis

Evidex Use Case: Analysis of DPP-4 Inhibitors

Posted by Andrea Demakas on Mar 24, 2016 10:30:00 AM

Last week we officially launched our revamped platform Evidex, which now includes easy-to-navigate evidence from both clinical trial data and real-world adverse event reports. To give you an idea of how simple it is to complete a thorough drug review in this platform, I'll go through a step-by-step overview of how to compare multiple diabetes meds.

Read More

Topics: Diabetes

Data, Disproportionality, & Drug Safety Communications

Posted by Andrea Demakas on Oct 30, 2014 11:00:00 AM

Last week, pharmacovigilance news outlets announced the confirmation of one case of a serious adverse reaction from the multiple sclerosis (MS) drug Tecfidera. Reuters noted that this coincided with a 7 percent drop in Biogen Idec shares. The point of discussion here is a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML). This adverse reaction led to the market withdrawal of Tysabri in 2005, and has been associated with other MS drugs as well. Tysabri was returned to the market after increased safety measures were put in place, including a risk minimization program. In 2012, the FDA posted a Drug Safety Communication stating a Boxed Warning would be added to another MS drug, Adcetris, after just 3 cases of PML were reported in patients taking this drug.

Read More

Topics: Drug Safety

How New-Agers and Hipsters are Popularizing Drug Safety

Posted by Andrea Demakas on Sep 5, 2014 2:30:00 PM

I’m not usually one to keep up with the latest trends, but I have been noticing how some of the fads from the past couple of years could actually make drug safety seem cool to the general public. Yes, I said it. We’re probably going to be extremely popular after this blog post goes out.

Hipsters are like cool nerds, with hats and extravagant mustaches. New-agers are like health nuts, with the addition of conspiracy theories and healing crystals. Are you starting to see where I am going with this? It’s okay if you don’t -- some people may think I’m making quite a leap. Let me explain.

Read More

Topics: Drug Safety, Big Pharma, Pharmacovigilance

How many links does it take to get to the center of an FDA FOIA request?

Posted by Andrea Demakas on Jul 24, 2014 1:30:00 PM

A Day in the Life of a Data Minion

Ever wonder what magic is happening behind the scenes at AdverseEvents? What goes into the process of data management before it shows up in your inbox, or you receive an email alert about breaking news in pharmacovigilance with data supplied by your favorite drug safety information specialists? Well, there’s a lot. And although it is not all glamorous, we tend to have fun doing it.

Read More

Topics: Big Data, FOIA, AdverseEvents, Inc, faers data

Subscribe to Email Updates